Patient-Reported Outcomes After Radiation Therapy for Dupuytren’s Contracture

IF 2.9 Q3 ONCOLOGY
Advances in Radiation Oncology Pub Date : 2026-09-01 Epub Date: 2026-09-11 DOI:10.1016/j.adro.2026.102161
Joyce Kuo BS, Alice Jiang BA, Yi Peng Wang BS, Amy Ladd MD, Catherine Curtin MD, Jeffrey Yao MD, Sarah S. Donaldson MD, Susan M. Hiniker MD, Justin Oh MD
{"title":"Patient-Reported Outcomes After Radiation Therapy for Dupuytren’s Contracture","authors":"Joyce Kuo BS,&nbsp;Alice Jiang BA,&nbsp;Yi Peng Wang BS,&nbsp;Amy Ladd MD,&nbsp;Catherine Curtin MD,&nbsp;Jeffrey Yao MD,&nbsp;Sarah S. Donaldson MD,&nbsp;Susan M. Hiniker MD,&nbsp;Justin Oh MD","doi":"10.1016/j.adro.2026.102161","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Dupuytren’s contracture (DC) is a fibroproliferative disorder that can result in functional impairment of the hand. Radiation therapy (RT) is used to prevent disease progression and sometimes as adjuvant therapy after surgeries and recurrences. However, comprehensive data on patient-reported efficacy are limited. This study aimed to assess patient-reported outcomes in patients with DC treated with primary and adjuvant RT.</div></div><div>Dupuytren’s contracture (DC) is a fibroproliferative disorder that can result in functional impairment of the hand. Radiation therapy (RT) is used to prevent disease progression and sometimes as adjuvant therapy after surgeries and recurrences. However, comprehensive data on patient-reported efficacy are limited. This study aimed to assess patient-reported outcomes in patients with DC treated with primary and adjuvant RT.</div><div><h3>Methods and Materials</h3><div>A single-institution retrospective study was conducted, including 22 patients treated with RT for DC between April 2017 and July 2022. Surveys to assess satisfaction, perceived effectiveness, and treatment burden used Likert scales and the post-RT Southampton Dupuytren’s Scoring Scheme. All patients received either 30 Gy in a split course or 21 Gy in continuous daily treatments.</div></div><div>A single-institution retrospective study was conducted, including 22 patients treated with RT for DC between April 2017 and July 2022. Surveys to assess satisfaction, perceived effectiveness, and treatment burden used Likert scales and the post-RT Southampton Dupuytren’s Scoring Scheme. All patients received either 30 Gy in a split course or 21 Gy in continuous daily treatments.</div><div><h3>Results</h3><div>Median follow-up was 4.3 years, and median age at diagnosis was 61 years. Sixty-three percent had undergone fasciectomy before RT. Seventy-seven percent expressed satisfaction with RT outcomes, and 68% perceived it as effective. Median post-RT Southampton Dupuytren’s Scoring Scheme score was 5 (IQR, 4-6), indicating mild functional limitations. Four patients (18%) experienced new nodules or cords, and only 1 patient (4.5%) required further surgery. Thirteen patients (59%) reported side effects from RT, most commonly mild dry skin. One patient developed severe dry skin, but there were no other severe toxicities or malignancies observed.</div></div><div>Median follow-up was 4.3 years, and median age at diagnosis was 61 years. Sixty-three percent had undergone fasciectomy before RT. Seventy-seven percent expressed satisfaction with RT outcomes, and 68% perceived it as effective. Median post-RT Southampton Dupuytren’s Scoring Scheme score was 5 (IQR, 4-6), indicating mild functional limitations. Four patients (18%) experienced new nodules or cords, and only 1 patient (4.5%) required further surgery. Thirteen patients (59%) reported side effects from RT, most commonly mild dry skin. One patient developed severe dry skin, but there were no other severe toxicities or malignancies observed.</div><div><h3>Conclusions</h3><div>RT for DC may be associated with high patient satisfaction and low toxicity. Although these findings are encouraging, they are hypothesis-generating and warrant confirmation in prospective studies with larger cohorts and systematic pretreatment and posttreatment assessments.</div></div><div>RT for DC may be associated with high patient satisfaction and low toxicity. Although these findings are encouraging, they are hypothesis-generating and warrant confirmation in prospective studies with larger cohorts and systematic pretreatment and posttreatment assessments.</div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102161"},"PeriodicalIF":2.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452109426001685","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Dupuytren’s contracture (DC) is a fibroproliferative disorder that can result in functional impairment of the hand. Radiation therapy (RT) is used to prevent disease progression and sometimes as adjuvant therapy after surgeries and recurrences. However, comprehensive data on patient-reported efficacy are limited. This study aimed to assess patient-reported outcomes in patients with DC treated with primary and adjuvant RT.
Dupuytren’s contracture (DC) is a fibroproliferative disorder that can result in functional impairment of the hand. Radiation therapy (RT) is used to prevent disease progression and sometimes as adjuvant therapy after surgeries and recurrences. However, comprehensive data on patient-reported efficacy are limited. This study aimed to assess patient-reported outcomes in patients with DC treated with primary and adjuvant RT.

Methods and Materials

A single-institution retrospective study was conducted, including 22 patients treated with RT for DC between April 2017 and July 2022. Surveys to assess satisfaction, perceived effectiveness, and treatment burden used Likert scales and the post-RT Southampton Dupuytren’s Scoring Scheme. All patients received either 30 Gy in a split course or 21 Gy in continuous daily treatments.
A single-institution retrospective study was conducted, including 22 patients treated with RT for DC between April 2017 and July 2022. Surveys to assess satisfaction, perceived effectiveness, and treatment burden used Likert scales and the post-RT Southampton Dupuytren’s Scoring Scheme. All patients received either 30 Gy in a split course or 21 Gy in continuous daily treatments.

Results

Median follow-up was 4.3 years, and median age at diagnosis was 61 years. Sixty-three percent had undergone fasciectomy before RT. Seventy-seven percent expressed satisfaction with RT outcomes, and 68% perceived it as effective. Median post-RT Southampton Dupuytren’s Scoring Scheme score was 5 (IQR, 4-6), indicating mild functional limitations. Four patients (18%) experienced new nodules or cords, and only 1 patient (4.5%) required further surgery. Thirteen patients (59%) reported side effects from RT, most commonly mild dry skin. One patient developed severe dry skin, but there were no other severe toxicities or malignancies observed.
Median follow-up was 4.3 years, and median age at diagnosis was 61 years. Sixty-three percent had undergone fasciectomy before RT. Seventy-seven percent expressed satisfaction with RT outcomes, and 68% perceived it as effective. Median post-RT Southampton Dupuytren’s Scoring Scheme score was 5 (IQR, 4-6), indicating mild functional limitations. Four patients (18%) experienced new nodules or cords, and only 1 patient (4.5%) required further surgery. Thirteen patients (59%) reported side effects from RT, most commonly mild dry skin. One patient developed severe dry skin, but there were no other severe toxicities or malignancies observed.

Conclusions

RT for DC may be associated with high patient satisfaction and low toxicity. Although these findings are encouraging, they are hypothesis-generating and warrant confirmation in prospective studies with larger cohorts and systematic pretreatment and posttreatment assessments.
RT for DC may be associated with high patient satisfaction and low toxicity. Although these findings are encouraging, they are hypothesis-generating and warrant confirmation in prospective studies with larger cohorts and systematic pretreatment and posttreatment assessments.
Dupuytren挛缩放射治疗后患者报告的结果
目的dupuytren 's挛缩(DC)是一种可导致手部功能损害的纤维增生性疾病。放射治疗(RT)用于预防疾病进展,有时作为手术后和复发后的辅助治疗。然而,关于患者报告疗效的综合数据有限。本研究旨在评估患者报告的DC患者接受原发性和辅助性rt治疗的结果。dupuytren 's挛缩(DC)是一种纤维增生性疾病,可导致手部功能损伤。放射治疗(RT)用于预防疾病进展,有时作为手术后和复发后的辅助治疗。然而,关于患者报告疗效的综合数据有限。本研究旨在评估接受初级和辅助放疗的DC患者报告的结果。方法和材料进行了一项单机构回顾性研究,包括2017年4月至2022年7月期间接受DC RT治疗的22例患者。评估满意度、感知有效性和治疗负担的调查使用李克特量表和放疗后南安普顿Dupuytren评分方案。所有患者均接受30 Gy的分割疗程或21 Gy的连续每日治疗。进行了一项单机构回顾性研究,包括2017年4月至2022年7月期间接受RT治疗的22例DC患者。评估满意度、感知有效性和治疗负担的调查使用李克特量表和放疗后南安普顿Dupuytren评分方案。所有患者均接受30 Gy的分割疗程或21 Gy的连续每日治疗。结果中位随访时间为4.3年,诊断时中位年龄为61岁。63%的患者在放疗前接受了筋膜切除术。77%的患者对放疗结果表示满意,68%的患者认为其有效。术后中位评分为5分(IQR, 4-6),提示轻度功能限制。4名患者(18%)出现新的结节或索,只有1名患者(4.5%)需要进一步手术。13名患者(59%)报告了放疗的副作用,最常见的是轻度皮肤干燥。一名患者出现严重的皮肤干燥,但没有观察到其他严重的毒性或恶性肿瘤。中位随访时间为4.3年,诊断时的中位年龄为61岁。63%的患者在放疗前接受了筋膜切除术。77%的患者对放疗结果表示满意,68%的患者认为其有效。术后中位评分为5分(IQR, 4-6),提示轻度功能限制。4名患者(18%)出现新的结节或索,只有1名患者(4.5%)需要进一步手术。13名患者(59%)报告了放疗的副作用,最常见的是轻度皮肤干燥。一名患者出现严重的皮肤干燥,但没有观察到其他严重的毒性或恶性肿瘤。结论srt治疗DC患者满意度高,毒性低。虽然这些发现是令人鼓舞的,但它们是假设产生的,需要在更大的队列和系统的治疗前和治疗后评估的前瞻性研究中得到证实。DC的放射治疗可能与高患者满意度和低毒性有关。虽然这些发现是令人鼓舞的,但它们是假设产生的,需要在更大的队列和系统的治疗前和治疗后评估的前瞻性研究中得到证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Radiation Oncology
Advances in Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
4.60
自引率
4.30%
发文量
208
审稿时长
98 days
期刊介绍: The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书